but just one thought/example to share .... our stock recently hit a high of 09. Why didn't we seize that opportunity to announce the RS and uplisting. The potential numbers sure looked favorable to me, especially coupled with the approval and start of the 100,000 stem cell injections?
Besides the possibility of having the court cases resolved, a intriguing possibility may be the wish to uplist after the "when not if" JV to be announced in the unknown future. That would be a position of strength.
Market Data 
Markets 
AI
